{
  "docId": "019de072-7463-7169-8f31-7c4d89e9eac4",
  "docSlug": "d88eea3c6872c4e67cae911eb0680043",
  "documentTitle": "argenx SE | Results Presentation Deck | 10 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 10,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a process flow diagram to illustrate the clinical trial methodology.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-7463-7169-8f31-7c4d89e9eac4/4",
  "deckHref": "/decks/019de072-7463-7169-8f31-7c4d89e9eac4",
  "deckJsonHref": "/decks/019de072-7463-7169-8f31-7c4d89e9eac4.json",
  "deckAnchorHref": "/decks/019de072-7463-7169-8f31-7c4d89e9eac4#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Flowchart showing screening, randomization (1:1), ADAPT phase (26 weeks), and ADAPT+ phase (up to 3 years).",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "918bca94-ac48-4c8b-adbd-ad4f55a19b62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.79,
        "y": 0.62
      },
      "kind": "legend",
      "text": "Arrows indicate treatment periods of 4 infusions at weekly intervals. Efgartigimod 10 mg/kg IV, Placebo.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec902e6f-f749-468f-85e4-9763ee860512",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.037,
        "y": 0.9
      },
      "kind": "paragraph",
      "text": "AChR, acetylcholine receptor; gMG, generalized myasthenia gravis; IgG, immunoglobulin G; IV, intravenous; MG-ADL, Myasthenia Gravis Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; Wk, week. Note: Patients requiring rescue therapy discontinued from the study treatment. a50% of the score attributed to nonocular items. bAcetylcholinesterase inhibitor, steroid +/or nonsteroidal immunosuppressive therapy (for the duration of the trial). c Based on clinical evaluation. Patients needed to have an MG-ADL score ≥5 (>50% from nonocular items) and needed to have a reduction in MG-ADL total score <2 points from study/cycle baseline to be eligible to receive a new cycle. 1. Howard JF Jr, et al. Lancet Neurol. 2021;20(7):526-536.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b93381d-973a-43f7-b92f-ff51d2120a6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.285,
        "x": 0.037,
        "y": 0.05
      },
      "kind": "title",
      "text": "ADAPT+ Study Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c11ea6b-4308-4355-af41-c105148f512f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "daee0c49-05e7-4401-9379-9809e5f66a58",
      "evidence": "The slide uses a flow diagram to represent the clinical trial stages.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 4,
      "beatId": "1159cb70-ce54-4b95-8784-abd8efb4d24a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation provides relief by showing the efficacy, safety, and tolerability of efgartigimod.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}